Virax Biolabs Group Limited cash flow to debt ratio of -1.10K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Virax Biolabs Group Limited's free cash flow has increased -30.28% from $-7.41M last year to $-5.17M, signaling increasing performance

Virax Biolabs Group Limited's debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Virax Biolabs Group Limited's debt has decreased relative to shareholder equity from 0.07 last year to 0.05 today, signaling strengthened financials

Virax Biolabs Group Limited has negative EBITDA, making leverage ratio unreliable

Virax Biolabs Group Limited's interest coverage ratio is -103.60, which means that the company struggles to meet interest obligations, signaling financial risk.

Virax Biolabs Group Limited's profit margin has increased (-57.76%) in the last year from -95.74K% to -40.44K%, signaling increasing performance

Virax Biolabs Group Limited's short-term assets of $6.83M exceed its short-term liabilities of $685.02K

Virax Biolabs Group Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Virax Biolabs Group Limited's return on equity of -77.95%, is lower than 15.00%, indicating bad performance

Virax Biolabs Group Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Virax Biolabs Group Limited had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Virax Biolabs Group Limited has negative free cash flow, indicating the company is burning cash rather than generating it

Virax Biolabs Group Limited has negative free cash flow, indicating cash burn

Virax Biolabs Group Limited's yearly earnings has increased -17.12% since last year from $-6.06M to $-5.02M, signaling increasing performance

Virax Biolabs Group Limited's yearly revenue has increased 96.22% since last year from $6.33K to $12.42K, signaling increasing performance

ROIC -82.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Virax Biolabs Group Limited's 3-year revenue CAGR of 13.21% is positive, indicating growing revenue over the past 3 years

Virax Biolabs Group Limited had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Virax Biolabs Group Limited had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Virax Biolabs Group Limited has insufficient data to evaluate this check.

Virax Biolabs Group Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Virax Biolabs Group Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Virax Biolabs Group Limited has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Virax Biolabs Group Limited is overvalued relative to its fair value price of -124.29 based on Earnings Fair Value model

Virax Biolabs Group Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Virax Biolabs Group Limited has a price-to-book ratio of 0.31x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Virax Biolabs Group Limited has a price-to-sales ratio of 181.55x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue